bq 788  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs bq 788
    Systemic administration of an ET A receptor antagonist, but not an ET B receptor antagonist, prevented oxaliplatin-induced mechanical allodynia and cold allodynia: Mechanical allodynia (a, b, d) and cold allodynia (c, e) were examined using the von Frey test and the acetone test, respectively. An ET A receptor antagonist, atrasentan (a–c), or an ET B receptor antagonist, <t>BQ-788</t> (d, e), was intraperitoneally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–8). (a, d) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (c, e) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h, 24 h and 4 days after oxaliplatin administration. * p
    Bq 788, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bq 788/product/Alomone Labs
    Average 93 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    bq 788 - by Bioz Stars, 2022-08
    93/100 stars

    Images

    1) Product Images from "Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats"

    Article Title: Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats

    Journal: Molecular Pain

    doi: 10.1177/17448069211058004

    Systemic administration of an ET A receptor antagonist, but not an ET B receptor antagonist, prevented oxaliplatin-induced mechanical allodynia and cold allodynia: Mechanical allodynia (a, b, d) and cold allodynia (c, e) were examined using the von Frey test and the acetone test, respectively. An ET A receptor antagonist, atrasentan (a–c), or an ET B receptor antagonist, BQ-788 (d, e), was intraperitoneally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–8). (a, d) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (c, e) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h, 24 h and 4 days after oxaliplatin administration. * p
    Figure Legend Snippet: Systemic administration of an ET A receptor antagonist, but not an ET B receptor antagonist, prevented oxaliplatin-induced mechanical allodynia and cold allodynia: Mechanical allodynia (a, b, d) and cold allodynia (c, e) were examined using the von Frey test and the acetone test, respectively. An ET A receptor antagonist, atrasentan (a–c), or an ET B receptor antagonist, BQ-788 (d, e), was intraperitoneally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–8). (a, d) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (c, e) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h, 24 h and 4 days after oxaliplatin administration. * p

    Techniques Used:

    Intrathecal administration of an ET A receptor antagonist prevented oxaliplatin-induced mechanical allodynia but not cold allodynia: Mechanical allodynia (a, c) and cold allodynia (b, d) were examined using the von Frey test and the acetone test, respectively. Atrasentan (50 μg) or BQ-788 (50 μg) was intrathecally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–6). (a, c) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (b, d) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h and 24 h after oxaliplatin administration. * p
    Figure Legend Snippet: Intrathecal administration of an ET A receptor antagonist prevented oxaliplatin-induced mechanical allodynia but not cold allodynia: Mechanical allodynia (a, c) and cold allodynia (b, d) were examined using the von Frey test and the acetone test, respectively. Atrasentan (50 μg) or BQ-788 (50 μg) was intrathecally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–6). (a, c) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (b, d) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h and 24 h after oxaliplatin administration. * p

    Techniques Used:

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Alomone Labs bq 788
    Systemic administration of an ET A receptor antagonist, but not an ET B receptor antagonist, prevented oxaliplatin-induced mechanical allodynia and cold allodynia: Mechanical allodynia (a, b, d) and cold allodynia (c, e) were examined using the von Frey test and the acetone test, respectively. An ET A receptor antagonist, atrasentan (a–c), or an ET B receptor antagonist, <t>BQ-788</t> (d, e), was intraperitoneally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–8). (a, d) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (c, e) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h, 24 h and 4 days after oxaliplatin administration. * p
    Bq 788, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bq 788/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bq 788 - by Bioz Stars, 2022-08
    93/100 stars
      Buy from Supplier

    Image Search Results


    Systemic administration of an ET A receptor antagonist, but not an ET B receptor antagonist, prevented oxaliplatin-induced mechanical allodynia and cold allodynia: Mechanical allodynia (a, b, d) and cold allodynia (c, e) were examined using the von Frey test and the acetone test, respectively. An ET A receptor antagonist, atrasentan (a–c), or an ET B receptor antagonist, BQ-788 (d, e), was intraperitoneally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–8). (a, d) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (c, e) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h, 24 h and 4 days after oxaliplatin administration. * p

    Journal: Molecular Pain

    Article Title: Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats

    doi: 10.1177/17448069211058004

    Figure Lengend Snippet: Systemic administration of an ET A receptor antagonist, but not an ET B receptor antagonist, prevented oxaliplatin-induced mechanical allodynia and cold allodynia: Mechanical allodynia (a, b, d) and cold allodynia (c, e) were examined using the von Frey test and the acetone test, respectively. An ET A receptor antagonist, atrasentan (a–c), or an ET B receptor antagonist, BQ-788 (d, e), was intraperitoneally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–8). (a, d) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (c, e) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h, 24 h and 4 days after oxaliplatin administration. * p

    Article Snippet: Oxaliplatin (Yakult Corporation, Tokyo, Japan) was diluted in 5% glucose solution (1 mg/mL) and intraperitoneally administered at a dose of 5 mg/kg at day 0. , Bosentan, a dual ETA /ETB receptor antagonist (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), atrasentan, a selective ETA receptor antagonist (Sigma-Aldrich, St Louis, MO, USA) and BQ-788, a selective ETB receptor antagonist (Alomone Labs, Jerusalem, Israel) were dissolved in 60% dimethylsulfoxide and 40% propylene glycol.

    Techniques:

    Intrathecal administration of an ET A receptor antagonist prevented oxaliplatin-induced mechanical allodynia but not cold allodynia: Mechanical allodynia (a, c) and cold allodynia (b, d) were examined using the von Frey test and the acetone test, respectively. Atrasentan (50 μg) or BQ-788 (50 μg) was intrathecally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–6). (a, c) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (b, d) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h and 24 h after oxaliplatin administration. * p

    Journal: Molecular Pain

    Article Title: Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats

    doi: 10.1177/17448069211058004

    Figure Lengend Snippet: Intrathecal administration of an ET A receptor antagonist prevented oxaliplatin-induced mechanical allodynia but not cold allodynia: Mechanical allodynia (a, c) and cold allodynia (b, d) were examined using the von Frey test and the acetone test, respectively. Atrasentan (50 μg) or BQ-788 (50 μg) was intrathecally administered for 2 consecutive days (days −1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 ( n = 5–6). (a, c) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (b, d) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h and 24 h after oxaliplatin administration. * p

    Article Snippet: Oxaliplatin (Yakult Corporation, Tokyo, Japan) was diluted in 5% glucose solution (1 mg/mL) and intraperitoneally administered at a dose of 5 mg/kg at day 0. , Bosentan, a dual ETA /ETB receptor antagonist (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), atrasentan, a selective ETA receptor antagonist (Sigma-Aldrich, St Louis, MO, USA) and BQ-788, a selective ETB receptor antagonist (Alomone Labs, Jerusalem, Israel) were dissolved in 60% dimethylsulfoxide and 40% propylene glycol.

    Techniques: